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Infrainguinal vein graft stenosis: Cutting balloon
angioplasty as the first-line treatment of choice
Peter A. Schneider, MD, Michael T. Caps, MD, MPH, and Nicolas Nelken, MD, Honolulu, Hawaii
Objective: The optimal treatment for hemodynamically significant infrainguinal vein bypass graft stenosis is not known.
This study compares three options as first choice for the revision of failing infrainguinal vein grafts: cutting balloon
angioplasty (CBA), standard percutaneous transluminal balloon angioplasty (PTA), and open surgical revision (OS).
Methods: Infrainguinal vein bypass graft lesions treated in a single institution during a 12-year period were evaluated.
Of these, 161 lesions in 124 infrainguinal bypasses (101 patients) were treated with OS (n  42), PTA (n  57), or
CBA (n  62). The initial indication for the bypass in these patients was limb salvage in 73% and claudication in 27%. The
primary outcome of interest was the development of vein graft occlusion or significant stenosis (>70%) as detected by
surveillance duplex ultrasound scanning or arteriography some time after repair.
Results: The stenosis-free patency rates at 48 months for OS, CBA, and PTA were 74%, 62%, and 34%, respectively. PTA
was associated with an increased risk of treatment failure compared with both OS (hazard ratio [HR], 3.9; P < .0001)
and CBA (HR, 3.1; P < .0001). There was no significant difference between OS and CBA (HR, 1.3 for CBA vs OS, P 
.6). Pseudoaneurysms developed in two CBA patients. One ruptured and required interposition graft, and one was
monitored.
Conclusion: Cutting balloon angioplasty is a reasonable, initial treatment for infrainguinal vein graft stenosis in most
patients. It is a safe, minimally invasive, outpatient procedure with patency rates that are comparable to OS and superior
to PTA. ( J Vasc Surg 2008;47:960-6.)Lower extremity bypass using autologous vein is an
effective and widely accepted procedure for the treatment
of lower extremity ischemia. However, infrainguinal vein
grafts develop stenoses that threaten their patency in up to
20% of the cases.1-3 The traditional treatment for a vein
bypass graft stenosis is open surgical revision, and these
reconstructions produce reasonable long-term patency
rates.1,4-6 In the endovascular era, there are competing
options for the treatment of hemodynamically significant
infrainguinal vein bypass graft stenosis that require compar-
ison with open surgical revision.
Open repair of vein bypass grafts has drawbacks: addi-
tional conduit is required, dissection through scar tissue to
achieve anastomosis with either an inflow or outflow artery
may be necessary, and surgical wound healing may delay
recovery. Although these operations are not typically asso-
ciated with significant morbidity, a stay in the hospital is
usually required. During the past 10 years, various studies
have evaluated the possibility of endovascular intervention
rather than open repair of failing vein grafts, with mixed
results.2,6-9 The benefit of endovascular intervention is that
these revisions can be performed in a less invasive manner
on an outpatient basis, but standard balloon angioplasty has
not generally been durable.
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960Cutting balloon angioplasty (CBA) is a more recent
development and has been used in various situations where
the results of standard balloon angioplasty have not been
satisfactory.10 Preliminary reports have suggested that CBA
of vein graft stenosis is feasible and may be a reasonable
treatment option.11,12 In this study, we compared open
surgery (OS), CBA, and percutaneous transluminal angio-
plasty (PTA) in the management of failing infrainguinal
vein bypass grafts.
METHODS
This study compared the efficacy of OS, CBA, and PTA
for the initial treatment of infrainguinal vein bypass graft
stenosis. A retrospective review from a prospectively col-
lected vascular database was conducted of all lower extrem-
ity infrainguinal vein bypass graft revisions at Kaiser Foun-
dation Hospital in Honolulu between January 1995 and
June 2007.
Study population. This study includes three distinct
phases, during which the management of failing infraingui-
nal vein grafts was modified to reflect available treatment
options. Between 1995 and 1998, graft repairs were per-
formed using OS preferentially, with PTA reserved for
patients who were at high risk for OS or in whom surgery
could not be performed. These included patients with high
medical comorbidities, lack of vein, and hostile anatomy for
surgery. Between 1999 and 2002, patients were treated
selectively with either OS or PTA according to the type of
lesion. Focal stenoses, especially in the body of the graft,
were treated with PTA. Longer lesions (extending3 cm)
were treated with OS. Since October 2002, PTA has been
abandoned in favor of CBA, which we have performed as
the first-line treatment. Open surgery has been reserved for
those in whom endovascular intervention has failed and
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patients with severe renal insufficiency, contrast allergy, and
small vein diameter. A feasibility study of the use of CBA
was performed that included our initial 8 cases.12
Bypass grafts were performed using reversed saphenous
vein. Patent but failing grafts that were treated by surgical
or endovascular means were included. Grafts revised after
thrombectomy or thrombolysis, or both, were excluded.
Demographic data, medical risk factors, and surgical and
endovascular variables were analyzed. Data collected in-
cluded the type of vein bypass, indications for bypass,
inflow and outflow vessels, time to stenosis after the initial
bypass procedure, location of vein graft stenosis, number of
lesions, treatment modality, complications, and recurrent
stenosis. Lesion length was not analyzed as a separate
variable. Graft lesions were identified by the recurrence of
ischemic symptoms, a change in findings at physical exam-
ination, or the use of infrainguinal vein graft duplex ultra-
sound (DUS) surveillance.
The standard surveillance protocol includes DUS map-
ping of the entire limb 6 weeks, at 6 months, and 12
months. If no lesions are present, surveillance is performed
annually. If lesions are present and are not repaired, graft
surveillance continues at an increased frequency of either
every 3 months or every 6 months, depending on the
discretion of the attending surgeon. The criteria for further
investigation with arteriography were DUS scan findings of
increased peak systolic velocity 300 cm/s, or a velocity
ratio of 3:1, or evidence of low flow (graft velocity 25
cm/s). Most of the graft stenoses were detected during
standard DUS surveillance. The same criteria were used to
monitor the grafts after revision.
During the study period, 173 vein bypass graft revisions
were performed. One of these had no follow-up data avail-
able, leaving 172 potential lesion treatments for analysis.
Because we did not want to bias the results of the study by
including multiple re-do procedures on a small number of
recalcitrant lesions and because the aim of the study was to
determine the optimal initial treatment modality for in-
frainguinal vein bypass graft lesions, all re-do procedures
performed using the same treatment modality on the same
lesion were excluded from the analysis a priori. We ex-
cluded a total of 11 re-do procedures performed on five
lesions (including 7 re-do PTA, 3 re-do CBA, and 1 re-do
OS), leaving 161 lesions for the analysis.
Stenoses treated a second time using a different modal-
ity were included in the analysis. For example, if a lesion was
treated with PTA and then failed and was later treated with
OS, both of these procedures were included in the analysis.
Of the 161 procedures analyzed, 150 were first-time pro-
cedures and 11 were re-do procedures performed on a
lesion using a different modality.
Technique of cutting balloon angioplasty. The
technique of CBA of infrainguinal vein graft stenosis has
been described.12 Clopidogrel was administered before the
procedure (75 mg/d) and continued for 1 month after the
procedure. In most cases, the sheath tip was placed just
proximal to the origin of the vein graft. Heparin wasadministered (75 to 100 U/kg) before guidewire passage
across the lesion.
A 0.014-inch diameter guidewire, with directional
catheter support, was used to enter the graft and cross the
lesion using road mapping. The balloon is inflated slowly,
over approximately 60 seconds, so the atherotomes are
centered by the expanding balloon, thus creating cleavage
planes in the sclerotic lesion that are separated from each
other along the inner circumference of the graft. The
cutting balloon diameter was sized to be larger than the
residual lumen within the graft at the site of the stenosis but
smaller than the final intended diameter of the graft.
After CBA, a standard angioplasty balloon sized to the
intended diameter of the vein graft on a 0.014-inch diam-
eter guidewire was advanced to the site of the lesion and
balloon angioplasty was performed. The angioplasty bal-
loon was brought to the intended profile of the vein graft
over 30 to 60 seconds, but was not oversized, and inflation
was maintained for a minimum of a minute and often for
several minutes. Patients were routinely discharged on the
day of the procedure.
Outcome assessment. The primary outcome studied
was the time from revision to the detection of “treatment
failure,” defined as either (1) graft occlusion or (2) a70%
recurrent bypass graft stenosis at the site of the target lesion
detected by either DUS imaging or contrast arteriography.
Standard primary patency was also calculated using the
graft as the unit of analysis to facilitate comparison of these
results with those of other studies. Surveillance after CBA,
PTA, and OS was performed in a similar manner and was
the same as that performed for standard infrainguinal vein
graft bypasses. A physical examination and DUS scan were
performed routinely6 weeks and at 6 months, 1 year, and
annually after infrainguinal bypass graft revision.
Vein graft lesions were categorized by their location
within the bypass graft. Contrast arteriography was per-
formed when clinically indicated for bypass grafts with
suspected hemodynamically significant stenosis or occlu-
sion based on either the DUS scan or the physical exami-
nation, or both. Annual studies were performed for the
lifetime of the patient or the graft.
Statistical analysis. Summary statistics were calcu-
lated, including means and standard deviations for contin-
uous variables and proportions for categoric variables. Be-
cause more than one lesion per graft may have been treated
(and oftentimes using different modalities), the estimates
were performed using the lesion (and not the graft) as the
unit of analysis. The proportion of lesions free from treat-
ment failure was estimated using the Kaplan-Meier method,
and survival curves were compared and tested for statistical
significance using the log-rank test. Cox proportional haz-
ards regression was used to identify risk factors for treat-
ment failure and to assess the association of treatment
modality with treatment failure while controlling for other
study variables. Owing to possible dependence of treat-
ment failure among lesions belonging to the same graft,
robust standard errors were used to calculate P values and
95% confidence intervals (CI).13 The data analysis was
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RESULTS
A total of 161 infrainguinal vein bypass stenoses were
treated in 124 bypass grafts in 101 patients. The character-
istics of these lesions, grafts, and patients are summarized in
Table I. The indication for bypass was limb salvage in 91
(73%) and claudication in 33 (27%). Among the 161
treated stenoses, 42 were treated with OS, 62 with CBA,
and 57 with PTA. Of the 42 lesions treated with OS, 23
were treated with inflow jump grafts, nine with outflow
jump grafts, and 10 with vein patches.
There were a total of 3736 lesion-months of follow-up,
including a mean of 23.4 months (range, 1-102 months)
per lesion treatment. The univariate analysis of study factors
associated with treatment failure is reported in Table II. In
the univariate analysis, factors associated (P  .05) with an
increased risk of treatment failure included the treatment
modality, the initial indication for graft placement, and the
Table I. Characteristics of patients, grafts, and vein graft
lesions in the study population
Characteristics Value
Patients, No. 101
Age, mean  SD y 70.5  10.4
Sex, male, No. (%) 58 (57.4)
Grafts, No. 124
Indication, No. (%)
Limb salvage 91 (73.4)
Claudication 33 (26.6)
Proximal anastomosis, No. (%)
CFA 94 (75.8)
SFA/PFA 11 (8.9)
POP 19 (15.3)
Distal anastomosis, No. (%)
AK POP 27 (21.8)
BK POP 55 (44.4)
Tibial 21 (16.9)
Pedal 21 (16.9)
Treated lesions 161
Lesions per graft, mean No. (range) 1.2 (1–4)
Lesion location, No. (%)
Proximal anastomosis 77 (47.8)
Body of graft 37 (22.0)
Distal anastomosis 47 (29.2)
Lesion treatment, No. (%)
1st time treatment 150 (93.2)
2nd time, new modality 11 (6.8)
Time interval from graft placement to
lesion appearance, No. (%)
Early (6 mon) 42 (26.1)
Intermediate (6-12 mon) 36 (22.4)
Late (12 mon) 83 (51.6)
Treatment modality, No. (%)
Open surgery 42 (26.1)
Cutting balloon angioplasty 62 (38.5)
Standard PTA 57 (35.4)
AK, Above knee; BK, below knee; CFA, common femoral artery; POP,
popliteal; PTA, percutaneous transluminal angioplasty; PFA, profunda fem-
oral arteries; SFA, superficial femoral artery; SD, standard deviation.number of lesions per graft.A statistically significant relationship was found be-
tween treatment modality and treatment failure (P 
.0001). PTA was associated with a significantly increased
risk of treatment failure compared with both OS (hazard
ratio [HR], 3.9; P  .0001) and CBA (HR, 3.1; P 
.0001). No statistically significant difference was found
between OS and CBA, with a HR of 1.3 for CBA vs OS
(P  .6). The association of treatment modality with the
primary outcome was not substantially changed by exclu-
sion of the 11 re-do procedures. There was no significant
difference when CBA was compared with OS (HR, 1.3;
95% CI, 0.5-3.4; P .5), but the difference was significant
when PTA was compared with OS (HR, 4.5; 95% CI,
1.8-11.2; P  .001).
The Kaplan-Meier curves for stenosis-free patency are
shown in Fig 1. At 24 months, the stenosis-free patency
rates were OS, 80%; CBA, 75%; and PTA, 36%. At 48
months, the stenosis-free patency rates were OS, 74%;
CBA, 62%; and PTA, 34%. Standard primary patency was also
calculated using the graft as t h e unit of analysis (Table III).
At 24 months, the primary patency rates were OS 83%;
CBA, 81%; and PTA, 40%. Mean length of follow-up was
28.4 months for OS, 21.9 months for CBA, and 21.4
months for PTA.
Technical success was achieved in 100% with OS, 98%
Table II. Univariate association of study variables with
the risk of either lesion restenosis or graft occlusion in
161 lesions
Factor HR (95% CI) P
Age, per 10 years 1.2 (0.9-1.5) .3
Sex, female vs male 1.2 (0.7-2.0) .4
Indication, limb salvage vs claudication 3.4 (1.7-6.9) .001
Proximal anastomosis .9
CFA (ref) 1.0
SFA/PFA 1.2 (0.6-2.3)
POP 1.1 (0.6-2.0)
Distal anastomosis .9
AK POP (ref) 1.0
BK POP 1.1 (0.6-2.1)
Tibial 0.9 (0.4-2.2)
Pedal 1.2 (0.5-2.3)
Lesions per graft, 2 vs 1 1.9 (1.1-3.0) .014
Lesion location .8
Proximal anastomosis (ref) 1.0
Body of graft 0.9 (0.5-1.7)
Distal anastomosis 0.8 (0.5-1.4)
Lesion revision, 2nd time vs 1st time 0.9 (0.4-2.0) .9
Lesion timing .6
Late, 12 mon (ref) 1.0
Intermediate, 6-12 mon 1.0 (0.6-1.8)
Early, 6 mon 1.3 (0.7-2.4)
Treatment modality .0001
Open surgery (ref) 1.0
Cutting balloon angioplasty 1.3 (0.6-2.8) .6
Standard PTA 3.9 (1.8-8.4) .0001
AK, Above knee; BK, below knee; CFA, common femoral artery;
CI, confidence interval; HR, hazard ratio; POP, popliteal; PTA, percutane-
ous transluminal angioplasty; PFA, profunda femoral arteries; SFA, superfi-
cial femoral artery; SD, standard deviation.with CBA, and 98% with PTA. Major complications after
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toma, and one wound infection that prolonged the hospital
stay (7%). Three significant complications were associated
with CBA (5%). A delayed vein graft rupture occurred on
postoperative day 5 necessitated urgent interposition vein
grafting. A small pseudoaneurysm developed in a second
patient that is still being monitored and has not required
treatment. One access site hematoma required surgical
drainage. After PTA, there were two major hematomas
(5%) and one intraprocedural rupture requiring emergency
graft replacement.
No patients died in this series. Overall, 11 instances of
graft thrombosis occurred in the study, but there was no
significant association between treatment modality and
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Fig 1. Comparison of treatment modalities. This graph repre-
sents freedom from occlusion or stenosis 70% after infrainguinal
vein bypass graft revision using different treatment modalities.
Curves were created using Kaplan-Meier method. Standard errors
were less than 10% in all treatment groups to 48 months. PTA,
percutaneous transluminal angioplasty.
Table III. Analysis of primary patency ratesa for open
surgery, cutting balloon angioplasty, and standard
percutaneous transluminal angioplasty
Patency % (N)
Follow-up period OS CBA PTA
Primary patency (%) at
0 months 100% (42) 98% (62) 98% (57)
6 months 95% (40) 90% (53) 62% (36)
1 year 90% (34) 88% (43) 47% (26)
2 years 83% (21) 81% (26) 40% (17)
3 years 77% (13) 67% (15) 37% (12)
CBA, cutting balloon angioplasty; OS, open surgery; PTA, percutaneous
transluminal angioplasty.
aThis analysis was performed with the graft as the unit of analysis (n 124).
For grafts with a history of multiple lesion treatments (n  31), the first
treatment (time of treatment and modality) were used as the index proce-
dure to calculate patency rates. The primary patency rate of standard balloon
angioplasty was significantly less (P  .0001, log-rank test) than the other
two treatment modalities at 6 months.graft thrombosis. The association between treatment mo-dality and outcome was driven primarily by recurrent ste-
nosis and not by graft thrombosis. The likelihood of repeat
stenosis or graft occlusion 1 year of treatment was 13%
after OS, 11% after CBA, and 55% after PTA.
Lesions treated in grafts placed for limb salvage were
associated with a 3.4-fold increase in the risk of treatment
failure compared with lesions treated in grafts placed for
claudication (P  .001). The Kaplan-Meier analysis of this
relationship is shown in Fig 2. Lesions treated in grafts with
2 lesions had a 1.9-fold increase in the risk of treatment
failure compared with lesions treated in grafts with solitary
lesions (P  .014). A stepwise Cox regression model with
backwards selection is shown in Table IV. Treatment mo-
dality, indication for surgery, and number of lesions per
graft were entered into the initial model. After accounting
for the effects of indication and treatment modality, the
number of lesions per graft was no longer associated with
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Fig 2. Comparison of indication for surgery. This graph repre-
sents freedom from occlusion or stenosis 70% after infrainguinal
vein bypass graft revision in patients presenting with either limb
salvage or claudication as the indication for bypass. Curves were
created using Kaplan-Meier method. Standard errors were less
than 10% in both groups to 48 months.
Table IV. Stepwise Cox regression model (with
backward selection) of factors associated with the risk of
either lesion restenosis or graft occlusion in 161 lesionsa
Factor HR (95% CI) P
Indication, limb salvage vs claudication 3.6 (1.7-7.6) .001
Treatment modality .0001
Open surgery (ref) 1.0
Cutting balloon angioplasty 1.6 (0.7-3.3) .3
Standard PTA 4.3 (2.0-9.2) .0001
CI, Confidence interval;HR, hazard ratio; PTA, percutaneous transluminal
angioplasty.
aVariables included in the initial model included (1) indication (limb salvage
vs claudication, (2) lesions per graft (2 vs 1), and (3) treatment modality.
Treatment modality and indication were retained in the model. There were
no statistically significant (P  .05) interactions between these three vari-
ables.treatment failure. Both initial indication for bypass and
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icantly associated with treatment failure. These results in-
dicate that after controlling for other study variables, treat-
ment modality retains a significant association with treatment
failure and this association is predominantly accounted for
by differences between both OS and CBA and PTA, but
not between OS and CBA. Early appearance of the lesion
after bypass (6months) and graft lesion location were not
associated with treatment failure in the univariate analysis
(Table II). N o statistically significant association was
found between the treatment modality and the lesion
location or the time after bypass at which the lesion was
treated (Table V).
DISCUSSION
The major limiting factor for long-term patency in vein
bypass grafts is recurrent stenosis. Among the competing
methods of repair of vein graft stenosis are OS, PTA, and
CBA. Open surgery has been the gold standard for many
years, but commits the patient to a re-do operation. PTA
has been widely reported and studied and offers the advan-
tage of a minimally invasive approach, but with limited
applicability to selected lesions and marginal long-term
durability. CBA has become available more recently and
only feasibility studies have been performed.
The traditional treatment for a vein graft stenosis,
identified in a patient with recurrent ischemia or with a
significant finding by surveillance, is to proceed with OS.
Assisted primary patency achieved by repairing a graft steno-
sis is generally better than the secondary patency that results
when repair is performed after the graft has occluded.14-16
The usual OS treatments include inflow or outflow jump
grafts for anastomotic lesions, and patch angioplasty or
interposition grafts for focal lesions within the body of the
graft. Open surgical reconstruction provides reasonable
long-term patency. Nguyen et al1 demonstrated that OS of
infrainguinal vein grafts resulted in a 5-year patency rate of
49% and a secondary patency rate of 80%. Landry et al3
demonstrated an 87% assisted primary patency at 5 years
after OS revision of vein bypass grafts. Sanchez et al6
reported an 86% primary patency at 21 months, and Ban-
dyk et al17 found an 85% primary patency rate at 5 years
Table V. Comparison of distribution of graft lesion
location and timing of appearance of graft lesion in the
three treatment groups
Variable PTA CBA OS Pa
Location of treated lesion .15
Proximal anastomosis 26 25 26
Body of graft 11 19 7
Distal anastomosis 20 18 9
Age of lesion .3
6 months 19 13 10
6 months 38 49 32
aP values obtained using 2.after OS.Open repair has significant drawbacks, however. An
additional conduit is required. An inflow or outflow jump
graft is often necessary because many of these lesions occur
at anastomoses. This frequently requires sharp dissection
through scar tissue to achieve anastomosis with either an
inflow or outflow artery, which may also be diseased. These
are not operations typically associated with significant mor-
bidity, but regional or general anesthesia and a stay in the
hospital are still required. Although results are good after
OS, surveillance is still needed and some failures of OS
require further repair.
The potential advantages of endovascular vs OS are
fewer in the case of vein graft revision than in many other
contemporary scenarios (eg, iliac angioplasty vs aortofem-
oral bypass), but there are compelling reasons to consider
an endovascular option. Endovascular intervention for a
failing infrainguinal bypass can be performed with local
anesthesia on an outpatient basis. There are no wound
healing or conduit issues. Certain medications, such as
clopidogrel, do not need to be discontinued for the proce-
dure. Endovascular intervention does not preclude the use
of OS at some later time.
During the past decade, several clinical studies have
evaluated the possibility of endovascular intervention
rather than OS of failing vein grafts. Some series have
suggested that PTA achieves results that are similar to OS:
● Avino et al2 demonstrated that the stenosis-free pa-
tency rate at 2 years was the same for bothOS and PTA
(63%) when patients were carefully selected for an
endovascular approach. Graft stenoses selected for
PTA were focal, short (2 cm), single lesions in grafts
that were3.5 mm in diameter and had been in place
for 3 months.
● Nguyen et al1 used PTA for focal, short (1.5 cm)
lesions in the body of the graft and achieved 48%
patency at 5 years.
● Tong et al18 used PTA to treat all-comers with vein
graft stenosis, and this resulted in patencies of 54% at 3
years and 45% at 5 years.
Most studies, however, demonstrated that the failure
rate for PTA was higher.
● Perler et al7 reported an experience consisting of 24
cases of PTA with a 3-year primary patency of 22%.
● Whittemore et al9 used PTA in 30 patients with 54
stenotic lesions, and the 5-year primary patency rate
was 18%.
● Other findings included 42% patency at 21 months by
Sanchez et al,6 39% patency at 1 year by Rua et al,19
36% patency at 1 year by Vikram et al,20 and 39%
patency at 2 years by Alexander and Katz.8
Most of the studies show that the success of PTA is less than
that of OS. Although success is improved somewhat with
very selective use of PTA, in most settings it is not durable
enough to be used as a mainstay of treatment. The findings
for OS and PTA in the present study are consistent with
these earlier studies: OS was significantly better than PTA,
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year and 34% at 4 years).
Cutting balloon angioplasty was initially introduced for
coronary applications because repeat coronary balloon an-
gioplasty alone has not been very effective. Since the devel-
opment of CBA several years ago, it has been used in a
variety of applications where the results of standard balloon
angioplasty have not been acceptable. The rationale for
CBA is that sclerotic lesions are cut, rather than ripped.
Predictable cleavage planes are created that can be
stretched, thus potentially avoiding unnecessary injury to
the intimal surface and erratic tearing of the stenosis.
Cutting balloon angioplasty for infrainguinal vein graft
stenosis was reported by Engelke et al11 in 2002. Kasirajan
et al12 reported results of a feasibility study in 2004: recur-
rence developed in only one patient of 19 at a mean of 11
months after CBA. More recent studies performed by
Garvin and Reifsnyder21 and Vikram et al20 have demon-
strated 6-month patencies of 48% and 80%, respectively, for
CBA in failing infrainguinal vein grafts. Differences in the
study populations and the manner in which CBA was used
in these two studies probably explain the difference in
results. However, these data suggest a need for longer-term
results and for comparison with the current standard of
open repair.
This study builds upon available data. Although previ-
ous studies reveal a wide range of patency rates for OS,
CBA, and PTA, to our knowledge, these three treatment
methods have not previously been directly compared in the
same study. The results of OS in the present study (4-year
patency of 74%) were within the published range of success
for OS repair. The results of PTA in this study (4-year
patency of 34%) were also comparable with previously
published studies. This study provides long-term results of
CBA for vein graft stenosis and comparative long-term data
with established treatments. Our findings indicate that
CBA is competitive with OS and superior to PTA.
The present study has several limitations. The treat-
ment groups were not randomized, and the potential for
treatment bias was present. The small cohort in each treat-
ment group could mask trends that may have become
apparent over time. The study was conducted during a
period in which treatment protocols, techniques, and de-
vice availability changed substantially.
In addition, the longitudinal nature of the study may
have introduced other unintended variables. There was an
increased use of clopidogrel and an institution-wide im-
provement in the use of statins. These changes are partially
controlled for by the fact that PTA was practiced most
commonly in between the periods of primary OS and
primary CBA.
Although the results of PTA were significantly different
than the other two modalities, the difference between OS
and CBA was not significant. The possibility remains that
the results of PTA might have been somewhat improved if
it had been used more regularly in the most recent period,
but the basic mechanism and balloon mechanics are the
same as in the earliest period. Whenever the results of PTAhave been compared with either OS or CBA, they have
almost always been substantially inferior.
Longer follow-up and larger treatment groups could
eventually reveal that CBA is inferior to OS. However, the
minimally invasive nature of CBA, along with the fact that
it does not preclude later use of OS if needed, contributes
to the concept that it is a reasonable initial treatment for
vein graft stenosis. We believe that a specific technique for
the use of cutting angioplasty is essential to avoid compli-
cations such as graft rupture and achieve acceptable long-
term results. If CBA is the selected treatment, it should be
performed as the initial treatment and not reserved only for
poor angiographic results of PTA.
The initial cutting balloon diameter is undersized to
the diameter of the graft but larger than the luminal diam-
eter at the stenosis to assist in avoiding rupture of the graft.
The cutting balloon is inflated slowly so that the athe-
rotomes are well separated, which allows the creation of
evenly spaced cleavage planes and avoids a deep incision in
nondiseased vein wall. The vein is further enlarged with a
standard balloon inflation that is sized to the intended
diameter of the vein and is used to deliberately and gradu-
ally stretch the sclerotic lesion, rather than rip it.
CONCLUSION
Cutting balloon angioplasty is a reasonable initial treat-
ment of choice for infrainguinal vein graft stenosis. It is a
safe, minimally invasive outpatient procedure with patency
rates that are comparable with open surgery and superior to
standard balloon angioplasty. Treatment of vein graft ste-
nosis with standard balloon angioplasty has been aban-
doned in our institution. Open surgery is reserved for
patients with recurrent lesions after cutting balloon angio-
plasty, and for those in whom an endovascular intervention
cannot be performed. Monitoring is required after cutting
balloon angioplasty, as with any type of revision.
AUTHOR CONTRIBUTIONS
Conception and design: PS, MC, NN
Analysis and interpretation: MC, PS
Data collection: PS, MC
Writing the article: PS, MC, NN
Critical revision of the article: PS, MC
Final approval of the article: PS, MC, NN
Statistical analysis: MC
Obtained funding: Not applicable
Overall responsibility: PS
REFERENCES
1. Nguyen LL, Conte MS, Menard MT, Gravereaux EC, Chew DK,
Donaldson MC, et al. Infrainguinal vein bypass graft revision: factors
affecting long-term outcome. J Vasc Surg 2004;40:916-23.
2. Avino AJ, Bandyk DF, Gonsalves AJ, Johnson BL, Black TJ, Zwiebel
BR, et al. Surgical and endovascular intervention for infrainguinal vein
graft stenosis. J Vasc Surg 1999;29:60-71.
3. Landry GJ, Moneta GL, Taylor LM, Edwards JM, Yeager RA, Porter
JM. Long-term outcome of revised lower extremity bypass grafts. J Vasc
Surg 2002;35:56-62.
JOURNAL OF VASCULAR SURGERY
May 2008966 Schneider, Caps, and Nelken4. BandykDF, Schmitt DD, SeabrookGR, AdamsMB, Towne JB.Monitor-
ing functional patency of in situ saphenous vein bypasses: the impact of a
surveillance protocol and elective revision. J Vasc Surg 1989;9:286-96.
5. O’Mara CS, Flinn WR, Johnson ND, Bergan JJ, Yao JS. Recognition
and surgical management of patent but hemodynamically failed arterial
grafts. Ann Surg 1981;193:467-76.
6. Sanchez LA, Suggs WD, Marin ML, Panetta TF, Wengerter TF, Veith
FJ. Is percutaneous balloon angioplasty appropriate in the treatment of
graft and anastomotic lesions responsible for failing vein bypasses? Am J
Surg 1994;168:97-101.
7. Perler BA, Osterman FA, Mitchell SE, Burdick JF, Williams GM.
Balloon dilatation versus surgical revision of infrainguinal autogenous
vein graft stenoses: long-term follow-up. J Cardiovasc Surg 1990;31:
656-61.
8. Alexander JQ, Katz SG. The efficacy of percutaneous transluminal
angioplasty in the treatment of infrainguinal vein bypass graft stenosis.
Arch Surg 2003;138:510-3.
9. Whittemore AD, DonaldsonMC, Polak JF, Mannick JA. Limitations of
balloon angioplasty for vein graft stenosis. J Vasc Surg 1991;14:340-5.
10. Tsetis D, Morgan R, Belli AM. Cutting balloons for the treatment of
vascular stenoses. Eur Radiol 2006;16:1675-83.
11. Engelke C, Morgan RA, Belli AM. Cutting balloon percutaneous
transluminal angioplasty for salvage of lower limb bypass grafts: feasi-
bility. Radiology 2002;223:106-14.
12. Kasirajan K, Schneider PA. Early outcome of cutting angioplasty of
infrainguinal vein graft stenosis. J Vasc Surg 2004;39:702-8.
13. Lin DY. Cox regression analysis of multivariate failure time data: the
marginal approach. Stat Med 1994;13:2233-47.
of Plavix [Sanofi-Aventis, Bridgewater, NJ], duration of the anti-14. Wixon CL, Mills JL, Westerband A, Hughes JD, Ihnat DM. An
economic appraisal of lower extremity bypass graft maintainance. J Vasc
Surg 2000;32:1-12.
15. Rhodes JM, Gloviczki P, Bower TC, Panneton JM, Canton LG,
Toomey BJ. The benefits of secondary interventions in patients with
failed or failing pedal bypass grafts. Am J Surg 1999;178:151-5.
16. EagletonMJ, Erez O, Srivastava SD, Henke PK, Upchurch GR, Stanley
JC, et al. Outcome of surgical and endovascular intervention for infrain-
guinal bypass anastomotic strictures. Vasc Endovascular Surg 2006;40:
11-22.
17. Bandyk DF, Bergamini TM, Towne JB, Schmitt DD, Seabrook GR.
Durability of vein graft revision: the outcome of secondary procedures.
J Vasc Surg 1991;13:200-10.
18. Tong Y, Matthews PG, Royle JP. Outcome of endovascular intervention
for infrainguinal vein graft stenosis. Cardiovasc Surg 2002;10:545-50.
19. Rua I, Calligaro KD, Dougherty MJ, Raviola CA, Doerr K, McAfee-
Bennett S, et al. Is balloon angioplasty indicated for “short” stenoses of
failing vein grafts? Ann Vasc Surg 1998;12:134-7.
20. Vikram R, Ross RA, Bhat R, Griffiths GD, Stonebridge PA, Houston
JG, et al. Cutting balloon angioplasty versus standard balloon angio-
plasty for failing infra-inguinal vein grafts: comparative study of short
and mid-term primary patency rates. Cardiovasc Intervent Radiol 2007;
30:607-10.
21. Garvin R, Reifsnyder T. Cutting balloon angioplasty of autogenous
infrainguinal bypasses: short-term safety and efficacy. J Vasc Surg 2007;
46:724-30.Submitted Sep 21, 2007; accepted Dec 13, 2007.DISCUSSION
Dr Kubaska III (Orange, Calif). Dr Schneider and his group
have presented a retrospective study comparing long-term results
of treating vein graft stenoses using cutting balloon angioplasty vs
more traditional treatments of open surgical revision and standard
balloon angioplasty. Cutting balloon angioplasty has been shown
in this study to be superior to standard balloon angioplasty and to
have comparable 4-year stenosis-free patency rates vs open surgical
revision of 62% vs 74%, respectively. These findings indicate that
cutting balloon angioplasty is competitive with open surgical revi-
sion in the initial treatment of infrainguinal vein graft stenosis.
The Achilles heel compromising long-term patency of infrain-
guinal vein bypass grafts is the development of stenoses from
intimal hyperplasia at the anastomotic or mid-graft locations asso-
ciated with vein valves. Using standard duplex imaging surveillance
protocols, stenosis can be localized and scheduled for treatment
prior to graft failure, thereby improving patency and longevity of
the graft.
I have a few questions for the authors. With cutting balloon
technology greatly changing over the period of the study, do you
think that this may have influenced the technical success of these
procedures and ultimately the long-term outcomes of the proce-
dures?
Have you used other types of cutting balloons or scoring
balloons prior to standard balloon angioplasty? At our institution,
we have recently started using the AngioSculpt [AngioScore Inc,
Fremont, Calif], a scoring balloon, to treat stenosis of infrainguinal
cryopreserved vein grafts, which are known to be prone to recur-
rent stenosis with favorable results.
Did you find that lesions in the body of the graft which are
usually associated with vein valves more or less difficult to treat
than anastomotic lesions and why?
And finally, do you think with the addition of antiplatelet
agents such as clopidogrel in conjunction with aspirin, the patency
rates following percutaneous interventions have improved over the
past decade? Could you comment on preprocedural administrationplatelet therapy, and in cases where patients do not tolerate long-
term antiplatelet drug administration?
I thank the program committee for the privilege of discussing
this paper and the authors for sending me their manuscript well
before the meeting for my review. Thank you.
Dr Schneider. Balloon angioplasty is definitely better now
than it was in the mid to late ’90s. Part of it is the equipment—the
devices that we have available—and the other is the pharmacolog-
ical manipulation that goes with it. However, vein graft lesions
have not changed. My impression before we did this study was that
balloon angioplasty gives you a great result about a third of the
time and you cannot really figure out why. A third look great after
balloon angioplasty and a third look like you didn’t do anything
and a third look like you ripped it. The nice thing about cutting is
that the vein graft lesion is usually a focal lesion, which is nice for
endo, and by cutting it first it gives you the ability to open it
without ripping it.
So, well what about balloon angioplasty? Results of a very
contemporary series might be better, and if it were, it would
probably be because of statins and antiplatelet agents and other
factors. Basic balloon mechanics have not changed. The results of
balloon angioplasty for vein graft lesions in this series was right in
line withmany series that have been performed in the past 10 years.
I do not think that we will go back to balloon angioplasty for vein
graft lesions. The reason is that the additional risk of cutting
angioplasty is low and because the cutting provides a coordinated
cut whereas the angioplasty will always be a little bit random.
About scoring balloons—the thing I like about the scoring
balloons is that you can get them in longer segments. This is a piece
of metal sort of intertwined around the outside of the balloon.
Maybe that will work nicely for diffuse tibial lesions, but we have
not tried them in the vein graft stenoses.
The lesions in the body of the graft: It is not a huge number
but we looked hard and really could not find a difference between
the different locations of the lesions and how they responded.
